JP2019516748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516748A5 JP2019516748A5 JP2018561278A JP2018561278A JP2019516748A5 JP 2019516748 A5 JP2019516748 A5 JP 2019516748A5 JP 2018561278 A JP2018561278 A JP 2018561278A JP 2018561278 A JP2018561278 A JP 2018561278A JP 2019516748 A5 JP2019516748 A5 JP 2019516748A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell carcinoma
- inhibitor
- seq
- renal cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 14
- 238000002512 chemotherapy Methods 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 3
- 229950002916 avelumab Drugs 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 40
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 9
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 9
- 229910052697 platinum Inorganic materials 0.000 description 6
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 102000048776 human CD274 Human genes 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 102000048119 human PDCD1LG2 Human genes 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341921P | 2016-05-26 | 2016-05-26 | |
| US62/341,921 | 2016-05-26 | ||
| US201662423358P | 2016-11-17 | 2016-11-17 | |
| US62/423,358 | 2016-11-17 | ||
| US201762471459P | 2017-03-15 | 2017-03-15 | |
| US62/471,459 | 2017-03-15 | ||
| PCT/EP2017/062213 WO2017202744A1 (en) | 2016-05-26 | 2017-05-22 | Pd-1 / pd-l1 inhibitors for cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516748A JP2019516748A (ja) | 2019-06-20 |
| JP2019516748A5 true JP2019516748A5 (OSRAM) | 2020-07-02 |
Family
ID=58745241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561278A Pending JP2019516748A (ja) | 2016-05-26 | 2017-05-22 | がんを治療するためのｐｄ−１／ｐｄ−ｌ１阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190144545A1 (OSRAM) |
| EP (1) | EP3464356A1 (OSRAM) |
| JP (1) | JP2019516748A (OSRAM) |
| KR (1) | KR20190012201A (OSRAM) |
| CN (1) | CN109195989A (OSRAM) |
| AU (1) | AU2017269675A1 (OSRAM) |
| BR (1) | BR112018073920A2 (OSRAM) |
| CA (1) | CA3025391A1 (OSRAM) |
| IL (1) | IL263178A (OSRAM) |
| MX (1) | MX2018014435A (OSRAM) |
| RU (1) | RU2018145184A (OSRAM) |
| SG (1) | SG11201810423XA (OSRAM) |
| TW (1) | TW201800108A (OSRAM) |
| WO (1) | WO2017202744A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101981873B1 (ko) * | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2714233C2 (ru) | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| AU2016280003B2 (en) | 2015-06-16 | 2021-09-16 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
| BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| MX2019003755A (es) * | 2016-10-06 | 2019-08-12 | Pfizer | Regimen de dosificacion de avelumab para el tratamiento de cancer. |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| CN111712494A (zh) | 2018-02-13 | 2020-09-25 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| KR20210091209A (ko) * | 2018-11-05 | 2021-07-21 | 머크 샤프 앤드 돔 코포레이션 | 암의 치료를 위한 항-tigit 항체의 투여 요법 |
| WO2020095184A1 (en) * | 2018-11-05 | 2020-05-14 | Pfizer Inc. | Combinations for treating cancer |
| CN113164599B (zh) * | 2018-12-24 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| AU2020318975A1 (en) * | 2019-07-22 | 2022-03-17 | Seagen Inc. | Humanized anti-LIV1 antibodies for the treatment of cancer |
| CN120437288A (zh) * | 2019-12-24 | 2025-08-08 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗卵巢癌的药物组合 |
| TWI845826B (zh) | 2020-03-20 | 2024-06-21 | 美商基利科學股份有限公司 | 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法 |
| IL297908A (en) | 2020-05-05 | 2023-01-01 | Teon Therapeutics Inc | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
| TW202325306A (zh) | 2021-09-02 | 2023-07-01 | 美商天恩治療有限公司 | 改良免疫細胞之生長及功能的方法 |
| WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
| WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
| KR20230128690A (ko) * | 2022-02-28 | 2023-09-05 | 주식회사 시선테라퓨틱스 | 핵산 복합체를 포함하는 폐암 예방 또는 치료용 조성물 |
| EP4554943A1 (en) | 2022-07-14 | 2025-05-21 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| KR101981873B1 (ko) * | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR20210143932A (ko) * | 2013-09-11 | 2021-11-29 | 메디뮨 리미티드 | 종양 치료용 항-ｂ7-ｈ1 항체 |
| CA2954508A1 (en) * | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| RU2714233C2 (ru) * | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| AU2016280003B2 (en) * | 2015-06-16 | 2021-09-16 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
-
2017
- 2017-05-22 WO PCT/EP2017/062213 patent/WO2017202744A1/en not_active Ceased
- 2017-05-22 AU AU2017269675A patent/AU2017269675A1/en not_active Abandoned
- 2017-05-22 US US16/304,338 patent/US20190144545A1/en not_active Abandoned
- 2017-05-22 EP EP17724821.8A patent/EP3464356A1/en not_active Withdrawn
- 2017-05-22 JP JP2018561278A patent/JP2019516748A/ja active Pending
- 2017-05-22 KR KR1020187037522A patent/KR20190012201A/ko not_active Withdrawn
- 2017-05-22 SG SG11201810423XA patent/SG11201810423XA/en unknown
- 2017-05-22 CN CN201780032522.1A patent/CN109195989A/zh active Pending
- 2017-05-22 BR BR112018073920-0A patent/BR112018073920A2/pt not_active Application Discontinuation
- 2017-05-22 RU RU2018145184A patent/RU2018145184A/ru not_active Application Discontinuation
- 2017-05-22 CA CA3025391A patent/CA3025391A1/en not_active Abandoned
- 2017-05-22 MX MX2018014435A patent/MX2018014435A/es unknown
- 2017-05-25 TW TW106117304A patent/TW201800108A/zh unknown
-
2018
- 2018-11-21 IL IL263178A patent/IL263178A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516748A5 (OSRAM) | ||
| RU2018145184A (ru) | Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования | |
| JP2020508317A5 (OSRAM) | ||
| JP2016520082A5 (OSRAM) | ||
| JP2014114288A5 (OSRAM) | ||
| RS59134B1 (sr) | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća | |
| JP2020529469A5 (OSRAM) | ||
| JP2019503387A5 (OSRAM) | ||
| JP2019508433A5 (OSRAM) | ||
| JP2018512402A5 (OSRAM) | ||
| Yoon et al. | Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy | |
| JP2022164894A (ja) | 非成人のヒトに対する抗ｃｄ３０抗体－薬物コンジュゲートの投与 | |
| WO2020243603A1 (en) | Dosing of bispecific t cell engager | |
| EP3463456A1 (en) | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers | |
| CN109806393B (zh) | 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途 | |
| EP3920970B1 (en) | Method for treating checkpoint inhibitors induced adverse events | |
| JPWO2020223702A5 (OSRAM) | ||
| JP7064544B2 (ja) | 癌の治療のための抗ｖｅｇｆｒ－２抗体と抗ｐｄ－ｌ１抗体との組み合わせ | |
| Kubiatowski et al. | Lung cancer immunotherapy in transplant patients and in patients with autoimmune diseases | |
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| WO2021119105A1 (en) | Combination therapy with liv1-adc and pd-1 antagonist | |
| EP4520333A1 (en) | Syk inhibitors for use in the treatment of immune checkpoint inhibition induced adverse events | |
| WO2019070497A1 (en) | POLY THERAPY AGAINST CANCER | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| Heidari et al. | Interdisciplinary approach in hematological cancers |